Cadrenal Therapeutics Inc (CVKD)
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
📉 **NEGATIVE** • Medium confidence analysis (70%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General